Advertisement

Topics

BMS ties with Janssen on Factor XIa inhibitor programme

06:02 EDT 17 Apr 2018 | PharmaTimes

Bristol-Myers Squibb and Johnson & Johnson group Janssen have announced a deal to work together on a Factor XIa (FXIa) inhibitor programme.

Original Article: BMS ties with Janssen on Factor XIa inhibitor programme

NEXT ARTICLE

More From BioPortfolio on "BMS ties with Janssen on Factor XIa inhibitor programme"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...